| Meta-analysis summary statistics for associations meeting genome-wide significance | |||||||
|---|---|---|---|---|---|---|---|
| Lead SNP | Biochemicals | EA/OA | Ntotal | EAF | Effect (SE) | Pmeta | Details |
| rs1260326 | glucose / mannose | T/C | 7310 | 0.41 | 0.041 (0.002) | 2.5·10-148 | show |
| rs1260326 | mannose | T/C | 7345 | 0.41 | -0.044 (0.002) | 1.3·10-77 | show |
| rs1260326 | alanine | T/C | 7344 | 0.41 | 0.013 (0.002) | 5.56·10-14 | show |
EA = effect allele; OA = other allele; EAF = frequency of effect allele;
| Summary of biological annotations | |
|---|---|
| SNP | rs1260326 |
| Chromosomal location | Chr2: 27,584,444 (2p23.3) |
| Gene (distance) | GCKR (0) |
| Predicted causal gene | GCKR |
| Gene/protein classification | - |
| Metabolite (Pathway) | glucose (Glycolysis, gluconeogenesis, pyruvate metabolism; Carbohydrate) mannose (Fructose, mannose, galactose, starch, and sucrose metabolism; Carbohydrate) |
| Biochemical locus-metabolite relationship | GCKR encodes the glucokinase regulatory protein which inhibits the glucokinase enzyme. A common missense mutation in GCKR is associated with decreased glucose and increased triglycerides [18678614] .Ratio interpretation: unclear. GCKR influences glucose levels, but in this study the stronger association is with mannose |
| eQTL associations | EIF2B4 (L) † |
† F = adipose tissue; S = skin cells; L = lymphoblastoid cells; H = liver cells;
| Medical information | |
|---|---|
| Complex trait associations | Breast size [22747683]; C-reactive protein [21300955,18439548]; Calcium levels [20705733]; Cardiovascular disease risk factors [21943158]; Cholesterol, total [20686565]; Chronic kidney disease [20383146]; Crohn's disease [21102463]; Fasting glucose-related traits [20081858]; Fasting glucose-related traits (interaction with BMI) [22581228]; Fasting insulin-related traits [20081858]; Fasting insulin-related traits (interaction with BMI) [22581228]; Hypertriglyceridemia [20657596]; LDL cholesterol [18179892]; Lipoprotein-associated phospholipase A2 activity and mass [23118302]; Liver enzyme levels (gamma-glutamyl transferase) [22001757]; Metabolic syndrome [22399527]; Non-albumin protein levels [22558069]; Platelet counts [22139419]; Serum albumin level [23022100]; Serum total protein level [23022100]; Sex hormone-binding globulin levels [22829776]; Triglycerides [19060906,18193044,18193043,19060911,20864672,20686565]; Triglycerides-Blood Pressure (TG-BP) [21386085]; Two-hour glucose challenge [20081857]; Urate levels [20884846,23263486]; Uric acid levels [19503597]; Waist Circumference - Triglycerides (WC-TG) [21386085]; Waist circumference and related phenotypes [18454146] |
| Known metabolite associations | Palmitic acid (16:0) plasma levels [23362303]; Palmitoleic acid (16:1n-7) plasma levels [23362303]; Phospholipid levels (plasma) [21829377]; Glucose/mannose [21886157]; Ala, Gln [22286219] |
| Inborn error of metabolism | - |
| Pharmacological information | |
|---|---|
| ChEMBL ID | CHEMBL1075152 |
| Drug information | Compounds with activity in ChEMBL |
| Locus information for top associated metabolite | |
|---|---|
HapMap2 imputation![]() | 1KGP imputation![]() |








